PTSD treatment paths compared for Missourians not sold yet

Start with the sentence most articles on this subject bury: the FDA's approval of the esketamine product covers depression that other treatment has failed, not PTSD. A clinic that implies otherwise has stepped past what the regulator signed off on.

PTSD and depression travel together, and marketing here blurs them on purpose, so the paths below keep their approval status intact.

Doubt, for the record, is ordinary. Our paid poll reached 443 Midwest adults in ten states. Their reactions to ketamine or esketamine therapy: 21 percent skeptical and 9 percent negative, set against 34 percent cautious but open and 18 percent hopeful or curious, with another 18 percent unaware of it. The figures are validated and final.

Path one: trauma-focused psychotherapy

Structured talk therapies built for post-traumatic stress are the most established option, with the deepest track record. They are demanding, take months rather than days, and ask you to work directly with material you have spent years avoiding.

Advantages: no medication, no driver, no dose. Costs: time, emotional load, and finding a clinician trained in the specific protocol rather than general counseling.

A preference in our data sits alongside this. Care without medication appealed to 64 percent of respondents, though only 25 percent knew what TMS was. Half the sample had not heard of TMS yet wanted to avoid medication, and 25 percent neither knew nor cared; of the TMS-aware, 13 percent weighted drug-free care heavily and 12 percent barely at all.

Path two: standard medication

Certain antidepressants carry approval for PTSD and are usually the first prescription. For many people they help. For many they do not, which is why you are reading this.

Our survey sized that frustration. Asked about their lives, 72 percent of respondents described first-line medicine leaving depression, anxiety, or PTSD unresolved, for themselves (37 percent), for someone close (22 percent), or both (13 percent); 28 percent reported neither.

Path three: device-based treatment

Transcranial magnetic stimulation is a non-drug option delivered in a clinic across many short sessions. Its approvals and evidence sit mainly in depression rather than PTSD, the same boundary problem as esketamine, and it belongs on the list because most people have never been told it exists; just 25 percent of our sample knew it.

Advantages: no sedation, and you drive yourself home. Costs: many appointments, and coverage that depends on documented history.

Path four: esketamine, the approved one

Spravato is an esketamine nasal spray approved for treatment-resistant depression. It is taken in a certified setting alongside an oral antidepressant, you are observed after the dose, and you do not drive for the rest of that day. Brain Recovery Centers describes how its Spravato sessions are run.

If your picture is depression that has not responded to adequate medication trials, this is a conversation with a real regulatory file behind it. If your main diagnosis is PTSD without that depression history, the honest answer is that this is not the approved use, and a clinician must explain the reasoning before anything else happens.

Awareness of this option is close to nil. Among our respondents, 73 percent had never encountered it, 21 percent had a name and nothing more, and 6 percent knew what it was.

Path five: off-label ketamine, in a clinic or in the mail

IV ketamine in a clinic is an older anesthetic used off label. Compounded ketamine shipped home after a telehealth visit is off label and unsupervised. Both are legal. Neither has an approved indication for PTSD or depression.

This is where the skepticism you arrived with earns its keep. Ketamine has recognized misuse potential, home delivery strips out monitoring that exists for a reason, and a business shipping a controlled substance on repeat has an interest in your continuing to receive it.

The further a version of this treatment gets from a supervised room, the more the burden of proof shifts to whoever is selling it.

How the paths compare on what people said they weigh

A survey cannot rank these clinically, but it can hold them against the criteria our respondents said they use.

• Regulatory standing: 59 percent treated FDA approval as a clincher or a major weight. Therapy and approved medications clear that bar for PTSD, esketamine clears it for treatment-resistant depression, and off-label ketamine clears it for neither.
• Coverage: insurance sat in the top two provider considerations of 85 percent, and 65 percent called it decisive or major. Established paths have billing routes; cash-pay programs usually do not.
• Distance: 43 percent ranked nearness in their top two, so paths needing many visits or a driver are the ones geography can defeat.
• Friction: given covered care with more hoops or faster self-pay, 51 percent took the hoops, with the rest split between paying (23 percent) and indecision (26 percent).

Who should sort this for you

Not a comparison article, this one included. Asked who could persuade them, respondents overwhelmingly named their own doctor (74 percent), well ahead of friends or relatives (18 percent), service members or first responders they follow online (4 percent), advertising (2 percent), and podcasters (1 percent). For a first appointment, 56 percent would choose their primary doctor; a psychiatrist or other mental health clinician was the pick of 23 percent.

If you carry TRICARE, ask your own doctor what that plan already covers before paying anyone outside it.

The limits of everything above

This compares how options are structured and regulated, not how well they work, and it is not medical advice. Our study measured public attitudes, not outcomes. Which path fits a person depends on diagnosis, history, and medications, and only a clinician who reviews them can answer.

If PTSD has brought you to a place where staying alive feels optional, please do not wait until the treatment paths are sorted. Call or text 988 anywhere in the U.S., and veterans can press 1. The Lifeline is open at every hour, someone will answer, and you can reach out before it becomes an emergency.

Methodology

All data here comes from Pollfish panel survey 395586438, which this publisher commissioned and paid for. Fieldwork closed on June 23, 2026, after 443 members of the general public in ten Midwest states, ages 18 to 64, had finished it; no one was screened for a diagnosis. Multi-answer items are shares of respondents and add past 100. Pollfish has completed validation of every number. This article reports only top-line results, so no figure here describes a subgroup, veterans and people with PTSD included.